Best Peptides for Weight Loss in 2026: Ranked by Clinical Evidence
Reviewed by Peptide Nerds Editorial · Updated March 2026
Best Peptides for Weight Loss in 2026: Ranked by Clinical Evidence
Key takeaways:
- Semaglutide (Wegovy/Ozempic) is the most proven and accessible weight loss peptide, with 14.9% average weight loss in clinical trials
- Tirzepatide (Zepbound/Mounjaro) outperforms semaglutide at up to 22.5% weight loss and is now FDA-approved
- Retatrutide posted the highest weight loss number ever recorded (28.7% in Phase 3), but it is not yet available outside clinical trials
- Research peptides like CJC-1295/Ipamorelin and AOD-9604 have far less clinical evidence for weight loss specifically
- We ranked all 7 options by the strength of published human data, not internet hype
Important: This article is for educational and informational purposes only. It is not medical advice. Some compounds discussed are investigational or used off-label. Always consult a qualified healthcare provider before starting any peptide protocol or weight loss medication. See our full medical disclaimer.
How we ranked these peptides
The peptide weight loss space is flooded with claims. Research forums, TikTok, and biohacking communities all have opinions. We cut through the noise by ranking based on one thing: published human clinical data.
Our criteria, in order of weight:
- Clinical trial results (randomized, placebo-controlled human studies)
- FDA approval status (regulatory validation)
- Real-world availability (can you actually get it right now?)
- Safety and tolerability profile
- Cost and accessibility
This means compounds with strong Phase 3 data rank higher than peptides with only animal studies or anecdotal reports. That distinction matters more than most people realize.
For a broader look at peptide-based weight loss strategies, see our weight loss peptides hub.
1. Semaglutide: the gold standard
Semaglutide is the most studied weight loss peptide on the planet. It is a GLP-1 receptor agonist that mimics the incretin hormone your gut releases after eating. The result: reduced appetite, slower gastric emptying, and improved blood sugar regulation.
The data. The landmark STEP 1 trial showed 14.9% average body weight loss at 68 weeks on the 2.4 mg weekly dose, compared to 2.4% for placebo (PMID: 33567185). Subsequent STEP trials confirmed these results across different populations, including people with Type 2 diabetes and cardiovascular disease.
Brands. Wegovy (approved for weight management) and Ozempic (approved for Type 2 diabetes, widely used off-label for weight loss). Both are manufactured by Novo Nordisk.
Availability. Widely available by prescription. Supply shortages that plagued 2023 and 2024 have largely stabilized. Compounding pharmacies also offer semaglutide, though regulatory pressure on compounders has increased.
Cost. Brand name runs $1,000 to $1,350 per month without insurance. With insurance or manufacturer coupons, some patients pay $25 to $300. Compounded versions range from $150 to $400 per month.
Pros: Most clinical data of any weight loss peptide. FDA-approved. Widely prescribed. Cardiovascular benefits confirmed in SELECT trial.
Cons: GI side effects (nausea, vomiting, diarrhea) are common, especially during dose titration. Weight regain after discontinuation is well-documented. Not the most effective option available anymore.
For a deeper dive, see our full guide on semaglutide for weight loss.
Get the Peptide Starter Kit (free)
A quick-start guide to GLP-1 peptides, dosing basics, and what to ask your doctor.
2. Tirzepatide: the new front-runner
Tirzepatide is a dual GIP/GLP-1 receptor agonist. It targets two incretin pathways instead of one, which appears to produce greater weight loss than GLP-1 agonism alone.
The data. The SURMOUNT-1 trial demonstrated 22.5% average weight loss at the highest dose (15 mg) over 72 weeks (PMID: 35658024). The head-to-head SURMOUNT-5 trial confirmed tirzepatide produces significantly more weight loss than semaglutide. For a detailed comparison, see our semaglutide vs. tirzepatide breakdown.
Brands. Zepbound (approved for weight management) and Mounjaro (approved for Type 2 diabetes). Both are manufactured by Eli Lilly.
Availability. FDA-approved and available by prescription. Supply has been more consistent than semaglutide in recent months, partly due to Lilly's manufacturing investments.
Cost. Brand name runs $1,000 to $1,100 per month without insurance. Lilly's direct-to-consumer LillyDirect program offers lower pricing for some patients. Compounded tirzepatide is available but faces the same regulatory scrutiny as compounded semaglutide.
Pros: Higher weight loss than semaglutide. FDA-approved. Similar or slightly better GI tolerability in some studies. Strong metabolic improvements beyond weight.
Cons: Still expensive without insurance. Newer drug means less long-term safety data than semaglutide. Same weight regain concerns upon discontinuation.
See also: tirzepatide for weight loss.
3. Retatrutide: highest numbers ever recorded
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors. Adding glucagon receptor activation appears to increase energy expenditure and drive significant liver fat reduction on top of the appetite suppression from GLP-1/GIP.
The data. Phase 3 results showed 28.7% average weight loss at the highest dose over 48 weeks, with the weight loss curve still trending downward at study end (PMID: 37385275). That is the largest weight loss number ever recorded in a controlled obesity trial.
Availability. Not available. Retatrutide is currently in Phase 3 clinical trials (TRIUMPH program) run by Eli Lilly. FDA approval, if granted, is expected no earlier than late 2027.
Cost. Unknown. Expected to be at or above tirzepatide pricing given its position as a next-generation compound.
Pros: Unprecedented weight loss data. Triple mechanism addresses energy expenditure (not just appetite). Strong liver fat reduction data.
Cons: Not available outside clinical trials. No long-term safety data. Cannot be legally obtained from legitimate sources right now.
For the full research breakdown, see retatrutide for weight loss.
4. Survodutide: a different dual agonist
Survodutide is a dual glucagon/GLP-1 receptor agonist developed by Boehringer Ingelheim. Unlike tirzepatide, which pairs GLP-1 with GIP, survodutide pairs GLP-1 with glucagon. This different combination targets energy expenditure more directly.
The data. Phase 2 results showed approximately 18.7% body weight loss at 46 weeks at the highest dose. Phase 3 trials (SYNCHRONIZE program) are ongoing, with primary results expected in 2026 or early 2027.
Availability. Not yet FDA-approved. Currently in Phase 3 clinical trials. Not available through any legitimate channel outside of trial enrollment.
Cost. Unknown. Pricing will depend on approval timeline and competitive positioning against tirzepatide and retatrutide.
Pros: Different mechanism than tirzepatide (glucagon instead of GIP). Strong Phase 2 data. Also being studied for MASH (liver disease), which could expand its clinical profile.
Cons: Phase 3 data not yet published. Not available. Less data than the top 3 options on this list.
5. CJC-1295/Ipamorelin: the growth hormone route
CJC-1295 and Ipamorelin are growth hormone releasing peptides (GHRPs). They work by stimulating your pituitary gland to produce more growth hormone, which can influence body composition by promoting fat oxidation and supporting lean muscle.
The data. These are research peptides. Published human data on weight loss specifically is limited. Most evidence comes from studies on growth hormone secretion, body composition changes in small cohorts, and clinical use for GH deficiency rather than obesity treatment. The weight loss community uses them based on the general principle that elevated GH promotes fat metabolism.
Availability. Available through peptide clinics, anti-aging practices, and some compounding pharmacies. They are not FDA-approved for weight loss. Regulatory status has shifted since the FDA's 2023 crackdown on certain compounded peptides, so sourcing requires due diligence.
Cost. Typically $150 to $350 per month through a peptide clinic, depending on dosing protocol and whether prescribed as a stack.
Pros: Targets body composition (fat loss plus muscle preservation). Well-tolerated in most users. Lower cost than GLP-1 medications. Can be combined with other approaches.
Cons: Weak evidence for weight loss compared to GLP-1 class drugs. Not FDA-approved for any weight-related indication. Results are more subtle and slower. Requires daily injections in most protocols.
For more on this stack, see our GLP-1 weight loss stack guide.
6. Tesamorelin: FDA-approved, but not for weight loss
Tesamorelin is a growth hormone releasing hormone (GHRH) analog. It is FDA-approved under the brand name Egrifta for reducing excess abdominal fat in HIV-positive patients with lipodystrophy. That approval gives it a regulatory pedigree most research peptides lack.
The data. Clinical trials for its approved indication showed significant reductions in visceral adipose tissue (belly fat) over 26 weeks. It does not produce large-scale total body weight loss like GLP-1 agonists. The interest in tesamorelin for general weight loss is driven by its visceral fat reduction and its status as an FDA-approved peptide, which makes some clinicians more comfortable prescribing it.
Availability. Available by prescription, but typically prescribed for its approved indication. Off-label prescribing for body composition exists through anti-aging and wellness clinics.
Cost. Brand name (Egrifta) is expensive, often $1,000+ per month. Some clinics offer compounded tesamorelin at lower cost, typically $200 to $400 per month.
Pros: FDA-approved (for a different indication). Targeted visceral fat reduction. Good safety profile from years of clinical use.
Cons: Not designed or approved for general weight loss. Does not produce the dramatic total weight loss of GLP-1 drugs. Expensive at brand pricing.
7. AOD-9604: popular but unproven
AOD-9604 is a modified fragment of human growth hormone (specifically, amino acids 177 to 191). It was originally developed as an anti-obesity drug candidate based on animal studies showing it mimicked the fat-burning effects of growth hormone without affecting blood sugar or growth.
The data. This is where AOD-9604 falls short. Despite promising animal research, human clinical trials have been disappointing. A Phase 2b clinical trial for obesity did not demonstrate statistically significant weight loss over placebo. The compound was subsequently shelved by its original developer. It has since been approved in Australia as a food supplement ingredient (not a drug), which is a very different regulatory bar.
Availability. Available through peptide clinics and research chemical suppliers. Not FDA-approved for any indication. Regulatory status varies by country.
Cost. $100 to $250 per month through peptide clinics, making it one of the more affordable options on this list.
Pros: Low side effect profile. Affordable compared to GLP-1 drugs. Does not affect blood sugar or growth.
Cons: Failed to show significant weight loss in human trials. Minimal published clinical evidence. Popularity is driven more by community anecdote than data.
Head-to-head comparison table
| Peptide | Avg Weight Loss | FDA Approved? | Available Now? | Monthly Cost | Best For |
|---|---|---|---|---|---|
| Semaglutide | 14.9% | Yes (Wegovy) | Yes | $150-$1,350 | Proven, accessible weight loss |
| Tirzepatide | 22.5% | Yes (Zepbound) | Yes | $200-$1,100 | Maximum available weight loss |
| Retatrutide | 28.7% | No (Phase 3) | No | TBD | Future option (2027+) |
| Survodutide | ~18.7% | No (Phase 3) | No | TBD | Watching list |
| CJC-1295/Ipamorelin | Modest (no large trials) | No | Yes (clinics) | $150-$350 | Body recomp, GH optimization |
| Tesamorelin | Visceral fat only | Yes (Egrifta, for HIV) | Yes (off-label) | $200-$1,000+ | Targeted belly fat reduction |
| AOD-9604 | Not significant in trials | No | Yes (clinics) | $100-$250 | Budget option (weak evidence) |
The bottom line
If your goal is weight loss and you want proven results, the data clearly points to two options: tirzepatide for maximum effectiveness, or semaglutide for the broadest evidence base and widest availability.
Retatrutide will likely take the top spot when it reaches the market, but it is not available today. Planning around a drug you cannot access is not a strategy.
Research peptides like CJC-1295/Ipamorelin, tesamorelin, and AOD-9604 occupy a different category. They may have a role in body composition optimization, but the clinical evidence for meaningful weight loss does not compare to GLP-1 class medications. Anyone telling you otherwise is selling you something the data does not support.
The best peptide for weight loss is the one backed by strong clinical evidence that you can actually access, afford, and tolerate. For most people in 2026, that means talking to a physician about semaglutide or tirzepatide.
Medical Disclaimer: The information on this website is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide protocol, medication, or supplement regimen. Individual results vary. We share published research and editorial analysis, not medical recommendations.
Sources
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) - New England Journal of Medicine, 2021
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) - New England Journal of Medicine, 2022
- Retatrutide Phase 3 Trial Results - New England Journal of Medicine, 2023
Get the Peptide Starter Kit (free)
Quick-start guide to GLP-1 peptides, dosing basics, and what to ask your doctor.